Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL403976 | 0.98 | GAA (0.58) | GAAMAPTRAPGEF4CYP3A4KDM4E | |
| SCHEMBL1999098 | 0.82 | GAA (0.55) | GAAMAPTRAPGEF4CYP3A4POLB | |
| Hydrochloric Acid SCHEMBL1402959 | 0.80 | GAA (0.53) | GAAMAPTRAPGEF4CYP3A4POLB | |
| SCHEMBL9232234 | 0.79 | RAPGEF4 (0.57) | GAAMAPTRAPGEF4CYP3A4KDM4E | |
| SCHEMBL27924446 | 0.79 | RAPGEF4 (0.57) | GAAMAPTRAPGEF4CYP3A4KDM4E | |
| SCHEMBL11287941 | 0.77 | RAPGEF4 (0.55) | GAAMAPTRAPGEF4CYP3A4KDM4E | |
| SCHEMBL838148 | 0.76 | RAPGEF4 (0.54) | GAARAPGEF4KDM4EPOLBALDH1A1 | |
| SCHEMBL29710420 | 0.76 | IDO1 (0.57) | MAPTRAPGEF4CYP3A4KDM4EPOLB | |
| SCHEMBL1132624 | 0.76 | IDO1 (0.57) | MAPTRAPGEF4CYP3A4KDM4EPOLB | |
| SCHEMBL30951588 | 0.76 | RAPGEF4 (0.54) | GAARAPGEF4KDM4EPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023118267-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023118267-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-06-29 | — | — | WO | disclosed |
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| EP-3670514-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10577327-B2 | Pyridine based ionic fluoride for catalyzing indole and tetrazole formation | KING ABDULAZIZ UNIVERSITY (SA) | 2020-03-03 | — | — | US | disclosed |
| US-9840470-B2 | Targeting GLI proteins in human cancer by small molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840470-B2 | Targeting GLI proteins in human cancer by small molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170283424-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| EP-2734042-B1 | TARGETING GLI PROTEINS IN HUMAN CANCER BY SMALL MOLECULES | UNIV CALIFORNIA (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-3061749-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-08-31 | — | — | EP | disclosed |
| EP-0486900-B1 | Process for the preparation of indoles | BAYER AG (DE) | 1996-09-04 | — | — | EP | disclosed |
| EP-0673781-A1 | Recording sheets containing amine salts and quaternary choline halides | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | disclosed |
| US-5179211-A | PROCESS FOR THE PREPARATION OF INDOLES | BAYER AKTIENGESELLSCHAFT (DE) | 1993-01-12 | — | — | US | disclosed |
| EP-0486900-A2 | Process for the preparation of indoles | BAYER AG (DE) | 1992-05-27 | — | — | EP | disclosed |
| US-4771063-A | PLANTS | MONTEDISON S.P.A (IT) | 1988-09-13 | — | — | US | disclosed |
| US-4069377-A | Polymerization of ethylenically unsaturated monomers employing secondary-aliphatic α-substituted azoalkanes | PENNWALT CORPORATION | 1978-01-17 | — | — | US | disclosed |
| US-4028344-A | FOAMING AGENTS, FREE RADICAL INITIATORS | PENNWALT CORPORATION (US) | 1977-06-07 | — | — | US | disclosed |
| US-4025502-A | POLYMERIZATION CATALYSTS, CURING AGENTS | PENNWALT CORPORATION (US) | 1977-05-24 | — | — | US | disclosed |
| US-3979412-A | Process for producing 3-anilino-5-pyrazolones | FUJI PHOTO FILM CO., LTD. (JA) | 1976-09-07 | — | — | US | disclosed |
| US-3933874-A | Method for preparing of β-anilino-β-hydrazinoacrylates | FUJI PHOTO FILM CO., LTD. (JA) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389020-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | GAA 3202/4885MAPT 602/4885RAPGEF4 3491/4885 |
| US-10577327-B2 | Pyridine based ionic fluoride for catalyzing indole and tetrazole formation | FLI1, ABL1, INMT | GAA 4236/4885MAPT 1723/4885RAPGEF4 912/4885 |
| US-20170283424-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | GAA 3202/4885MAPT 602/4885RAPGEF4 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.